QURE Valuation

Uniqure NV

Add to Watchlist

Advanced Chart

14.120

+0.84(6.325%)1D

Overview
Forecast
Valuation
Earnings

QURE Relative Valuation

QURE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, QURE is overvalued; if below, it's undervalued.

Historical Valuation

Uniqure NV (QURE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 23.45 is considered Overvalued compared with the five-year average of -7.57. The fair price of Uniqure NV (QURE) is between 8.01 to 14.12 according to relative valuation methord. Compared to the current price of 14.12 USD , Uniqure NV is Overvalued By 0.01%.

Relative Value

Fair Zone

8.01-14.12

Current Price：14.12

0.01%

Overvalued

-3.97

Trailing

Forward

-7.21

EV/EBITDA

Uniqure NV. (QURE) has a current EV/EBITDA of -7.21. The 5-year average EV/EBITDA is -3.50. The thresholds are as follows: Strongly Undervalued below -33.21, Undervalued between -33.21 and -18.36, Fairly Valued between 11.35 and -18.36, Overvalued between 11.35 and 26.20, and Strongly Overvalued above 26.20. The current Forward EV/EBITDA of -7.21 falls within the Historic Trend Line -Fairly Valued range.

-5.39

EV/EBIT

Uniqure NV. (QURE) has a current EV/EBIT of -5.39. The 5-year average EV/EBIT is 5.27. The thresholds are as follows: Strongly Undervalued below -42.09, Undervalued between -42.09 and -18.41, Fairly Valued between 28.95 and -18.41, Overvalued between 28.95 and 52.63, and Strongly Overvalued above 52.63. The current Forward EV/EBIT of -5.39 falls within the Historic Trend Line -Fairly Valued range.

23.45

Uniqure NV. (QURE) has a current PS of 23.45. The 5-year average PS is 13.15. The thresholds are as follows: Strongly Undervalued below -15.46, Undervalued between -15.46 and -1.15, Fairly Valued between 27.46 and -1.15, Overvalued between 27.46 and 41.76, and Strongly Overvalued above 41.76. The current Forward PS of 23.45 falls within the Historic Trend Line -Fairly Valued range.

-7.78

P/OCF

Uniqure NV. (QURE) has a current P/OCF of -7.78. The 5-year average P/OCF is -12.81. The thresholds are as follows: Strongly Undervalued below -73.32, Undervalued between -73.32 and -43.06, Fairly Valued between 17.44 and -43.06, Overvalued between 17.44 and 47.69, and Strongly Overvalued above 47.69. The current Forward P/OCF of -7.78 falls within the Historic Trend Line -Fairly Valued range.

-6.73

P/FCF

Uniqure NV. (QURE) has a current P/FCF of -6.73. The 5-year average P/FCF is -1.48. The thresholds are as follows: Strongly Undervalued below -57.83, Undervalued between -57.83 and -29.66, Fairly Valued between 26.69 and -29.66, Overvalued between 26.69 and 54.86, and Strongly Overvalued above 54.86. The current Forward P/FCF of -6.73 falls within the Historic Trend Line -Fairly Valued range.

Uniqure NV (QURE) has a current Price-to-Book (P/B) ratio of -189.97. Compared to its 3-year average P/B ratio of -5.18 , the current P/B ratio is approximately 3565.63% higher. Relative to its 5-year average P/B ratio of -1.38, the current P/B ratio is about 13681.09% higher. Uniqure NV (QURE) has a Forward Free Cash Flow (FCF) yield of approximately -19.27%. Compared to its 3-year average FCF yield of -35.47%, the current FCF yield is approximately -45.68% lower. Relative to its 5-year average FCF yield of -17.02% , the current FCF yield is about 13.18% lower.

-189.97

P/B

Median3y

-5.18

Median5y

-1.38

-19.27

FCF Yield

Median3y

-35.47

Median5y

-17.02

Competitors Valuation Multiple

The average P/S ratio for QURE's competitors is 33.69, providing a benchmark for relative valuation. Uniqure NV Corp (QURE) exhibits a P/S ratio of 23.45, which is -30.38% above the industry average. Given its robust revenue growth of -52.71%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Tango Therapeutics Inc

Stoke Therapeutics Inc

Taysha Gene Therapies Inc

Nurix Therapeutics Inc

12.23

264.34%

737.74M

Performance Decomposition

Market capitalization of QURE increased by 141.37% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.43 to -3.60.

The secondary factor is the Margin Expansion, contributed 41.66%to the performance.

Overall, the performance of QURE in the past 1 year is driven by P/E Change. Which is more unsustainable.

-52.71%

11.13M → 5.26M

Revenue Growth

41.66%

-506.01 → -716.82

Margin Expansion

152.42%

-1.43 → -3.60

P/E Change

141.37%